REG-Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply
Globe Newswire•06/10/2026•16:30 ET
0
Key Highlights
- ➤LOTTE Biologics to manufacture multiple antibody biosimilars at Syracuse facility
- ➤Syracuse facility has 40,000 liters of biologics bioreactor capacity
- ➤Partnership expands Alvotech’s US manufacturing footprint and global supply network
- ➤Alvotech expects sufficient manufacturing capacity for its pipeline for the next ten years
- ➤Commercial supply depends on technology transfer, qualification, and regulatory approvals
Expert Statements
Lisa Graver, CEO of Alvotech
“Alvotech has one of the most comprehensive, internally developed product portfolios in the industry.”
Lisa Graver, CEO of Alvotech
“With the expansion of our global manufacturing network, we will have sufficient capacity to meet demand for our pipeline for the next ten years.”
Lisa Graver, CEO of Alvotech
“Our collaboration with LOTTE Biologics will bring additional manufacturing capacity in New York to support patients worldwide, complementing our existing capabilities as we scale our portfolio and prepare for future launches.”
James Park, CEO of LOTTE Biologics
“Alvotech’s expertise in biosimilar development, combined with LOTTE Biologics’ manufacturing capabilities, creates a strong foundation for this collaboration.”
James Park, CEO of LOTTE Biologics
“We look forward to strategically supporting Alvotech’s growing portfolio and the reliable supply of high-quality, more affordable biologic medicines to patients worldwide.”
James Park, CEO of LOTTE Biologics
“With our Syracuse operations and the completion of our Songdo Bio Campus, we are committed to providing flexible, dual-site manufacturing support as the partnership grows.”
Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics’ Syracuse facility in New York
Strategic long-term partnership to increase Alvotech’s global manufacturing capacity and support growth in demand
Get started
Create a free account to read the full story.